ArticleFrontiers in oncology2022

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.

Xiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.